METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental prostate cancer pill trial halted early
Disease control TerminatedThis early-stage study tested a new drug called TQB3720 in men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find a safe dose and see how the drug moves through the body. Up to 192 men were planned, but the study was stopped early. The …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 08:33 UTC
-
Cancer drug combo trial halted early after enrolling only 13 patients
Disease control TerminatedThis study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with an NRG1 gene fusion, and metastatic prostate cancer that no longer responds to hormone therapy. The trial was stopped early after enroll…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Partner Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 08:32 UTC
-
New prostate cancer combo study halted early
Disease control TerminatedThis study tested a new drug (exicorilant) combined with a standard treatment (enzalutamide) in 39 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find a safe dose and check for side effects. The study was terminated early, so results…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 08:25 UTC
-
New prostate cancer drug study halted early
Disease control TerminatedThis study aimed to test the safety and effectiveness of new drugs for men with a type of advanced prostate cancer that no longer responds to hormone therapy. It enrolled 65 adults with confirmed cancer. The study was terminated early, so results are limited.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental drug acapatamab targets Hard-to-Treat prostate cancer
Disease control TerminatedThis early-stage study tested a new drug called acapatamab in 212 men with metastatic castration-resistant prostate cancer that had stopped responding to standard therapies. The drug works by directing the body's immune cells to attack cancer cells. The main goals were to check s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Promising combo for resistant prostate cancer falls short
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combination was safe and could delay cancer …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control TerminatedThis study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals were …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:49 UTC